* 泰国富豪谢氏家族旗下制药公司--中国生物制药1177.HK周五早盘涨幅扩大至2.3%。
* 该公司此前公告称，联合开发的LM-108已被中国国家药品监督管理局药品审评中心纳入突破性治疗药物程序，用于联合特瑞普利单抗治疗既往接受一线标准治疗失败的CCR8阳性晚期胃╱胃食管结合部腺癌。
* 中国生物制药今年迄今劲涨64.4%，同期恒生指数.HSI大幅上扬21.8%。
* 恒生香港上市生物科技指数.HSHKBIO盘中一度跌1.7%。（完）
更多股市简讯请点选CN-CMN-HOT
(发稿 徐凯文；审校 吴云凌)
((kaiwen.xu@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.